421 related articles for article (PubMed ID: 21330577)
1. EZH2 protein: a promising immunomarker for the detection of hepatocellular carcinomas in liver needle biopsies.
Cai MY; Tong ZT; Zheng F; Liao YJ; Wang Y; Rao HL; Chen YC; Wu QL; Liu YH; Guan XY; Lin MC; Zeng YX; Kung HF; Xie D
Gut; 2011 Jul; 60(7):967-76. PubMed ID: 21330577
[TBL] [Abstract][Full Text] [Related]
2. From large to small: the immunohistochemical panel in the diagnosis of early hepatocellular carcinoma.
Vasuri F; Malvi D; Bonora S; Fittipaldi S; Renzulli M; Tovoli F; Golfieri R; Bolondi L; D'Errico A
Histopathology; 2018 Feb; 72(3):414-422. PubMed ID: 28881044
[TBL] [Abstract][Full Text] [Related]
3. Prospective validation of an immunohistochemical panel (glypican 3, heat shock protein 70 and glutamine synthetase) in liver biopsies for diagnosis of very early hepatocellular carcinoma.
Tremosini S; Forner A; Boix L; Vilana R; Bianchi L; Reig M; Rimola J; Rodríguez-Lope C; Ayuso C; Solé M; Bruix J
Gut; 2012 Oct; 61(10):1481-7. PubMed ID: 22287594
[TBL] [Abstract][Full Text] [Related]
4. Glypican-3 as a useful diagnostic marker that distinguishes hepatocellular carcinoma from benign hepatocellular mass lesions.
Wang HL; Anatelli F; Zhai QJ; Adley B; Chuang ST; Yang XJ
Arch Pathol Lab Med; 2008 Nov; 132(11):1723-8. PubMed ID: 18976006
[TBL] [Abstract][Full Text] [Related]
5. Utility of an immunohistochemical panel consisting of glypican-3, heat-shock protein-70, and glutamine synthetase in the distinction of low-grade hepatocellular carcinoma from hepatocellular adenoma.
Lagana SM; Salomao M; Bao F; Moreira RK; Lefkowitch JH; Remotti HE
Appl Immunohistochem Mol Morphol; 2013 Mar; 21(2):170-6. PubMed ID: 22914605
[TBL] [Abstract][Full Text] [Related]
6. The application of markers (HSP70 GPC3 and GS) in liver biopsies is useful for detection of hepatocellular carcinoma.
Di Tommaso L; Destro A; Seok JY; Balladore E; Terracciano L; Sangiovanni A; Iavarone M; Colombo M; Jang JJ; Yu E; Jin SY; Morenghi E; Park YN; Roncalli M
J Hepatol; 2009 Apr; 50(4):746-54. PubMed ID: 19231003
[TBL] [Abstract][Full Text] [Related]
7. [Expression and clinicopathologic significance of GPC3 and other antibodies in well-differentiated hepatocellular carcinoma].
DU JL; Wei LX; Wang YL
Zhonghua Bing Li Xue Za Zhi; 2011 Jan; 40(1):11-6. PubMed ID: 21429352
[TBL] [Abstract][Full Text] [Related]
8. Annexin A2 as a differential diagnostic marker of hepatocellular tumors.
Longerich T; Haller MT; Mogler C; Aulmann S; Lohmann V; Schirmacher P; Brand K
Pathol Res Pract; 2011 Jan; 207(1):8-14. PubMed ID: 20971570
[TBL] [Abstract][Full Text] [Related]
9. Glypican-3 expression distinguishes small hepatocellular carcinomas from cirrhosis, dysplastic nodules, and focal nodular hyperplasia-like nodules.
Libbrecht L; Severi T; Cassiman D; Vander Borght S; Pirenne J; Nevens F; Verslype C; van Pelt J; Roskams T
Am J Surg Pathol; 2006 Nov; 30(11):1405-11. PubMed ID: 17063081
[TBL] [Abstract][Full Text] [Related]
10. A structured proteomic approach identifies 14-3-3Sigma as a novel and reliable protein biomarker in panel based differential diagnostics of liver tumors.
Reis H; Pütter C; Megger DA; Bracht T; Weber F; Hoffmann AC; Bertram S; Wohlschläger J; Hagemann S; Eisenacher M; Scherag A; Schlaak JF; Canbay A; Meyer HE; Sitek B; Baba HA
Biochim Biophys Acta; 2015 Jun; 1854(6):641-50. PubMed ID: 25448011
[TBL] [Abstract][Full Text] [Related]
11. Concomitant use of heat-shock protein 70, glutamine synthetase and glypican-3 is useful in diagnosis of HBV-related hepatocellular carcinoma with higher specificity and sensitivity.
Moudi B; Heidari Z; Mahmoudzadeh-Sagheb H; Alavian SM; Lankarani KB; Farrokh P; Randel Nyengaard J
Eur J Histochem; 2018 Jan; 62(1):2859. PubMed ID: 29569872
[TBL] [Abstract][Full Text] [Related]
12. Diagnostic accuracy of clathrin heavy chain staining in a marker panel for the diagnosis of small hepatocellular carcinoma.
Di Tommaso L; Destro A; Fabbris V; Spagnuolo G; Laura Fracanzani A; Fargion S; Maggioni M; Patriarca C; Maria Macchi R; Quagliuolo M; Borzio M; Iavarone M; Sangiovanni A; Colombo M; Roncalli M
Hepatology; 2011 May; 53(5):1549-57. PubMed ID: 21520170
[TBL] [Abstract][Full Text] [Related]
13. Insulin-like growth factor II mRNA-binding protein 3 (IMP3) expression in hepatocellular carcinoma. A clinicopathological analysis with emphasis on diagnostic value.
Wachter DL; Kristiansen G; Soll C; Hellerbrand C; Breuhahn K; Fritzsche F; Agaimy A; Hartmann A; Riener MO
Histopathology; 2012 Jan; 60(2):278-86. PubMed ID: 22211286
[TBL] [Abstract][Full Text] [Related]
14. [Significance of glypican-3 immunohistochemistry in diagnosis of hepatocellular carcinoma].
Yip YC; Wang FH; Vong HT; Zhang M; Wen JM
Zhonghua Bing Li Xue Za Zhi; 2011 Sep; 40(9):626-9. PubMed ID: 22177248
[TBL] [Abstract][Full Text] [Related]
15. Utility of glypican-3 and survivin in differentiating hepatocellular carcinoma from benign and preneoplastic hepatic lesions and metastatic carcinomas in liver fine-needle aspiration biopsies.
Nassar A; Cohen C; Siddiqui MT
Diagn Cytopathol; 2009 Sep; 37(9):629-35. PubMed ID: 19405109
[TBL] [Abstract][Full Text] [Related]
16. The overexpression of polycomb group proteins Bmi1 and EZH2 is associated with the progression and aggressive biological behavior of hepatocellular carcinoma.
Sasaki M; Ikeda H; Itatsu K; Yamaguchi J; Sawada S; Minato H; Ohta T; Nakanuma Y
Lab Invest; 2008 Aug; 88(8):873-82. PubMed ID: 18591938
[TBL] [Abstract][Full Text] [Related]
17. Lentivirus-mediated RNA interference targeting enhancer of zeste homolog 2 inhibits hepatocellular carcinoma growth through down-regulation of stathmin.
Chen Y; Lin MC; Yao H; Wang H; Zhang AQ; Yu J; Hui CK; Lau GK; He ML; Sung J; Kung HF
Hepatology; 2007 Jul; 46(1):200-8. PubMed ID: 17596871
[TBL] [Abstract][Full Text] [Related]
18. Value of glypican 3 immunostaining in the diagnosis of hepatocellular carcinoma on needle biopsy.
Anatelli F; Chuang ST; Yang XJ; Wang HL
Am J Clin Pathol; 2008 Aug; 130(2):219-23. PubMed ID: 18628090
[TBL] [Abstract][Full Text] [Related]
19. MicroRNA-101 inhibits human hepatocellular carcinoma progression through EZH2 downregulation and increased cytostatic drug sensitivity.
Xu L; Beckebaum S; Iacob S; Wu G; Kaiser GM; Radtke A; Liu C; Kabar I; Schmidt HH; Zhang X; Lu M; Cicinnati VR
J Hepatol; 2014 Mar; 60(3):590-8. PubMed ID: 24211739
[TBL] [Abstract][Full Text] [Related]
20. A molecular signature to discriminate dysplastic nodules from early hepatocellular carcinoma in HCV cirrhosis.
Llovet JM; Chen Y; Wurmbach E; Roayaie S; Fiel MI; Schwartz M; Thung SN; Khitrov G; Zhang W; Villanueva A; Battiston C; Mazzaferro V; Bruix J; Waxman S; Friedman SL
Gastroenterology; 2006 Dec; 131(6):1758-67. PubMed ID: 17087938
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
